Coverage of COVID-19 tests and treatment bills halted for uninsured; Moderna low-dose vaccine in children under 6 years of age shows promise in early clinical trial findings; Pfizer recalls blood pressure medications due to potential carcinogen.
With Biden administration’s request for an additional $22.5 billion in ongoing COVID-19 response remains at an impasse in Congress, the Associated Press is reporting that the Uninsured Program, which provides COVID-19 care to approximately 28 million uninsured Americans, is being halted. Reimbursement claims for COVID-19 tests and treatment bills are no longer being taken as of midnight, Tuesday, March 22, with the program announcing it will stop accepting claims for vaccination-related costs after April 5. This comes as the CDC confirmed data yesterday indicating that the highly infectious COVID-19 Omicron BA.2 subvariant has been increasing in prevalence nationwide.
Moderna announced today it will seek emergency use authorization of its 2-dose COVID-19 vaccine in children under 6 years of age after early clinical trial results showed the low-dose shots produced high levels of antibodies against the virus—although it was less effective against the Omicron variant. In addition to expanding vaccine access to the last age group of the population who are not yet eligible to be vaccinated against COVID-19 Moderna will also seek approval for a larger-dose shot in older US children and teenagers, Associated Press reported. A mass rollout plan had been tentatively planned for Pfizer/BioNTech’s low-dose COVID-19 vaccine in children aged 6 months to 5 years last month, but the FDA announced it is seeking more data that is expected to become available in early April.
NPR is reporting that Pfizer issued a recall of its blood pressure medication Accuretic and 2 other versions of the drug, quinapril and hydrochlorothiazide tablets, due to increased levels of a potential cancer causing carcinogen in several tainted lots. Prescribed for patients with hypertension to reduce the risk of cardiovascular events, the presence of nitrosamine, a compound commonly found in water and food, was shown to be elevated above the acceptable daily intake level. Pfizer said no adverse events have been reported related to the drugs and that the recall is voluntary, with long-term exposure indicated to increase the risk of cancer.
Insurance Payer Is Associated With Length of Stay After Traumatic Brain Injury
February 21st 2025Among hospitalized patients with traumatic brain injury, Medicaid fee-for-service was associated with longer hospital stays than private insurance and Medicaid managed care organizations.
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
NSCLC Advancements Offer Hope, but Disparities Persist
February 20th 2025Ioana Bonta, MD, Georgia Cancer Specialists, discusses the evolving state of non-small cell lung cancer (NSCLC) treatments, their impact on patient outcomes, and the need to address ongoing disparities in these populations.
Read More
Abortion in 2025: Access, Fertility, and Infant Mortality Updates
February 20th 2025While Republican state-led efforts aim to increase restrictions to abortion care and access to mifepristone and misoprostol in 2025, JAMA authors join the conversation with their published research and commentary.
Read More
Adapting ACA Access Amid Medicaid Transition and Policy Reversals: Molly Dean
February 19th 2025As enrollment shifts to the Affordable Care Act (ACA) marketplace following the unwinding of Medicaid and the Trump administration begins to implement health policy changes, Molly Dean, MSW, Siftwell's policy advisor, shares insight on how to adapt.
Read More